Algert Global’s Aerie Pharmaceuticals AERI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-15,269
Closed -$231K 1339
2022
Q3
$231K Sell
15,269
-14,171
-48% -$165K 0.01% 1011
2022
Q2
$221K Buy
+29,440
New +$207K 0.02% 998
2022
Q1
Sell
-15,233
Closed -$107K 1356
2021
Q4
$107K Sell
15,233
-3,310
-18% -$34.6K 0.01% 913
2021
Q3
$211K Sell
18,543
-2,717
-13% -$39.7K 0.03% 894
2021
Q2
$340K Buy
21,260
+4,470
+27% +$76.7K 0.11% 258
2021
Q1
$300K Buy
16,790
+4,460
+36% +$77K 0.1% 301
2020
Q4
$167K Buy
+12,330
New +$149K 0.05% 358
2020
Q3
Sell
-12,090
Closed -$178K 510
2020
Q2
$178K Sell
12,090
-1,535
-11% -$22.7K 0.06% 340
2020
Q1
$184K Buy
+13,625
New +$259K 0.08% 309

Algert Global's AERI Position: Q4 2022 in Review

Algert Global sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 15,269 shares — an estimated $231K sold.

Algert Global first reported a position in AERI in Q1 2020 and held it in 9 quarters. The position peaked at $340K in Q2 2021. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.

  • Algert Global reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Algert Global sold 15,269 Aerie Pharmaceuticals shares in Q4 2022, an estimated $231K.
  • Algert Global first reported a position in Aerie Pharmaceuticals in Q1 2020 and held it in 9 quarters.
  • Algert Global's Aerie Pharmaceuticals position peaked at $340K in Q2 2021.
  • 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.

Based on Algert Global's 13F filing for Q4 2022, filed 14 Feb 2023.